Pharmacyclics (PCYC) PT Lifted to $175 at Nomura on Strong Q3
Tweet Send to a Friend
Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating and boosted its price target on Pharmacyclics (NASDAQ: PCYC) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE